Immunotherapy in surgically resectable non-small cell lung cancer.

about

Immunotherapy in surgically resectable non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q52624364

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Immunotherapy in surgically resectable non-small cell lung cancer.

@en

Immunotherapy in surgically resectable non-small cell lung cancer.

@nl

type

Item

label

Immunotherapy in surgically resectable non-small cell lung cancer.

@en

Immunotherapy in surgically resectable non-small cell lung cancer.

@nl

prefLabel

Immunotherapy in surgically resectable non-small cell lung cancer.

@en

Immunotherapy in surgically resectable non-small cell lung cancer.

@nl

P1476

Immunotherapy in surgically resectable non-small cell lung cancer

@en

P2093

Jamie E Chaft

http://www.w3.org/2001/XMLSchema#string

P2860

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Pembrolizumab for the treatment of non-small-cell lung cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.

P304

S404-S411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JTD.2017.12.93

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 3

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dwight Owen

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29593886

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5861266

http://www.w3.org/2001/XMLSchema#string